Korea’s Anti-Rebate Task Force Raids Dong-A Pharmaceutical
This article was originally published in PharmAsia News
A South Korean task force aimed at rooting out illegal drug rebates, raided the head office of top domestic drug company Dong-A in which GlaxoSmithKline and Otsuka Pharmaceutical hold stakes.
You may also be interested in...
SEOUL - South Korea's leading pharma company Dong-A Pharmaceutical Co. will join the biosimilar sector, years behind its domestic competitors. The company signed a memorandum of understanding with the Korean authorities to build a biosimilar plant in collabration with Japan's Meiji Seika Pharma Co. Ltd. at the Songdo Free Economic Zone in Incheon City, about 10 miles west of Seoul
Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence
SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.